文献速递肾移植急性肾损伤肾小球疾病

肾移植术后血栓性微血管病:遗传病因与临床结局

Thrombotic Microangiopathy After Kidney Transplantation: Insights Into Genetic Etiology and Clinical Outcomes.
PubMed 文献 · Kidney Int Rep · 2025-01-30

该单中心回顾性研究纳入2008至2023年3535例肾移植受者,68例诊断为移植后血栓性微血管病(TMA),其中93%接受基因检测。按病因分三组:补体介导组(62%)复发TMA者33%,其中约78%失去移植物;钙调神经磷酸酶抑制剂(CNI)或缺血再灌注损伤(IRI)组冷缺血时间更长且延迟移植物功能率更高;其他病因组对补体治疗反应差。结论强调移植前后基因检测和基于意义未明变异(VUS)功能评估的个体化策略。

要点

  • 移植后TMA患者应完善补体相关基因检测以明确病因。
  • 补体介导TMA复发者移植物丢失风险高,需密切监测。
  • CNI相关TMA与更长冷缺血时间和更高DGF率相关。

核心结论

  • 肾移植术后TMA需综合移植前后基因检测以预测和管理风险、防止移植物丢失。
  • CNI在存在其他补体激活因素时可能增加移植后TMA风险。
  • 基于VUS功能评估的个体化策略和早期干预具有重要意义。

研究设计与样本

  • 单中心回顾性研究,纳入2008至2023年3535例肾移植受者。
  • 68例诊断为TMA,其中93%(63/68)接受基因检测。
  • 按病因分为三组:补体介导组42例(62%)、CNI或IRI相关组14例(21%)、其他病因组12例(17%)。

主要发现

  • 补体介导组患者更年轻,且高血压或子痫前期作为ESKD病因的比例更高。
  • 补体介导组33%发生TMA复发,复发者中约78%失去移植物。
  • CNI或IRI相关组冷缺血时间较对照更长(19.9±8.7小时 vs. 10.7±8.9小时;P=0.0001)。
  • CNI或IRI相关组延迟移植物功能率高于对照(43% vs. 13%,P=0.0008)。
  • 其他病因组对补体治疗反应差,未发现基因变异。

临床怎么用

  • 对移植后TMA患者应进行补体相关基因检测以区分病因。
  • 补体介导TMA患者需警惕复发并及时干预以降低移植物丢失。
  • 对CNI相关TMA应关注冷缺血时间和DGF风险。
  • 对VUS应进行功能评估以指导个体化治疗。

局限性

  • 单中心回顾性设计可能限制结果外推。
  • 其他病因组样本量较小(12例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Thrombotic microangiopathy (TMA), characterized by small-vessel thrombosis caused by endothelial injury, presents significant diagnostic and treatment challenges in kidney transplantation. METHODS: To investigate the factors associated with posttransplant TMA, we conducted a retrospective study of 3535 kidney transplant recipients at our center from 2008 to 2023. RESULTS: Sixty-eight patients were diagnosed with TMA, and 93% (63 of 68) underwent genetic testing. Patients were categorized into 3 groups based on the TMA etiology. Group 1 (n = 42, 62%) included patients with complement-mediated TMA associated with genetic or acquired complement abnormalities. These patients were younger and had a higher incidence of hypertension (HTN) or preeclampsia as the causes of end-stage kidney disease (ESKD). Notably, 33% of patients developed recurrent TMA, and approximately 78% of those with recurrent TMA lost their allografts. Group 2 (n = 14, 21%) had TMA associated with calcineurin inhibitors (CNIs) or ischemia-reperfusion injury (IRI), showing longer cold ischemia times (CITs) (19.9 ± 8.7 hours vs. 10.7 ± 8.9 hours; P = 0.0001) and a higher rate of delayed graft function (DGF) (43% vs. 13%, P = 0.0008) than the controls. Group 3 (n = 12, 17%) had TMA from diverse causes (infections or autoimmune disorders) and exhibited a poor response to anticomplement therapy. No genetic variants were identified in this group. CONCLUSION: Our findings underscore the need for comprehensive pre and posttransplantation genetic testing to predict and manage the risk of TMA and prevent graft loss. CNIs may exacerbate the risk of posttransplant TMA in the presence of other complement-activating factors. Our study also highlights the importance of personalized strategies and early interventions based on the functional assessment of variants of uncertain significance (VUS).

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Merzkani M, Chann Wai Lynn N, Flores K, et al. Thrombotic Microangiopathy After Kidney Transplantation: Insights Into Genetic Etiology and Clinical Outcomes. Kidney Int Rep. 2025. PMID: 40303217. doi:10.1016/j.ekir.2025.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。